{"filings":[{"id":748757,"accession_number":"0001193125-26-248680","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-05-29T21:04:54+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tenaya shareholders approve amended equity plan adding 6.5M shares, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2021 Equity Incentive Plan with one-time increase of 6,509,966 shares (~3% of outstanding).","Annual evergreen cap removed; future yearly increase remains 4% of outstanding shares per fiscal year.","Class II directors Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen elected with >86M votes each.","Deloitte & Touche ratified as independent auditor for FY2026 with 135.6M votes for.","Plan amendments also limit shares issuable as incentive stock options to 15M total."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96328,"accession_number":"0001193125-26-208975","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.","Alnylam collaboration: $10M upfront, up to $1.1B milestones; cash runway into H2 2027 inclusive of upfront.","TN-201 (HCM gene therapy): interim Cohort 2 data and Cohort 1 update expected Q2 2026; enrollment resumed after protocol amendments.","TN-401 (ARVC gene therapy): one-year Cohort 1 and initial Cohort 2 data to be presented at ASGCT May 15, 2026.","TN-301 (HDAC6i) granted Rare Pediatric and Orphan Drug Designation for DMD; preclinical data showed improved grip strength."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":225000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110142,"accession_number":"0001193125-26-102170","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.","Cash, equivalents and investments $100.5M at Dec 31, 2025; December offering net $55.8M plus Alnylam upfront extend runway into H2 2027.","TN-201 (HCM) and TN-401 (ARVC) gene therapies: interim data presented; enrollment resumed; plans for regulatory alignment in 2026.","Entered multi-target collaboration with Alnylam: $10M upfront, up to $1.1B milestones; Alnylam handles development and commercialization.","TN-301 (HDAC6i) preclinical DMD data: improved grip strength to wild-type levels at 3 mg/kg, outperforming givinostat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110141,"accession_number":"0001193125-26-092654","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.","Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.","Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.","Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.","Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110140,"accession_number":"0001193125-26-032017","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.","Company has 180 days, until July 27, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive business days.","If not cured, Tenaya may transfer to Nasdaq Capital Market for second 180-day compliance period, subject to eligibility and application.","Board approved increase in Inducement Plan shares by 2,161,000 to a total of 3,361,000 shares for new-hire equity grants.","Inducement Plan amendment effective Jan 26, 2026; awards limited to new employees as material inducement under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110139,"accession_number":"0001193125-26-001065","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David Goeddel resigns from Tenaya board effective Jan 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Goeddel submitted resignation from the Board and all committees on Dec 31, 2025. Effective Jan 26, 2026.","Resignation due to retirement; no disagreement with Company on operations, policies, or practices.","Board thanked Dr. Goeddel for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126685,"accession_number":"0001193125-25-317642","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices $60M public offering of 50M units at $1.20/unit; warrants at $1.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$60M from 50M units, each unit = 1 share + 1 warrant (5-yr, $1.50 exercise).","Underwriters: Leerink Partners, Piper Sandler, LifeSci Capital. Closing expected Dec 15, 2025.","Proceeds to fund development of TN-201 and TN-401 and for working capital and general purposes.","Warrant coverage at 100%; shares and warrants immediately separable on issuance.","60-day lockup for officers, directors, and certain stockholders unless consent is given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126684,"accession_number":"0001193125-25-315951","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on TN-201; TN-401 shows positive interim data in ARVC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA removed clinical hold on MyPEAK-1 trial for TN-201 gene therapy; protocol amendments implemented, dosing to resume.","TN-401 well tolerated at 3E13 vg/kg; no dose-limiting toxicities or thrombotic microangiopathy observed.","Robust transduction and PKP2 protein increase in 2 of 3 patients; vector copy numbers 3.4 and 5.0 per genome.","Clinically meaningful arrhythmia reduction: Patient 1 PVCs -46%, Patient 2 PVCs -89% and NSVT from 78 to 0.","One-year Cohort 1 and early Cohort 2 data for TN-201 and TN-401 expected in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126683,"accession_number":"0001193125-25-273230","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q3 net loss $20.3M; FDA places clinical hold on TN-201 MyPEAK-1 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $20.3M ($0.12/share) vs $25.6M ($0.30) in Q3 2024; cash $56.3M, sufficient into H2 2026.","FDA placed clinical hold on MyPEAK-1 trial of TN-201 (MYBPC3 HCM) after proactive FDA outreach; company expects resolution without impacting timelines.","New TN-201 data at AHA: Cohort 1 patients at ≥52 weeks showed durable reductions in hypertrophy and biomarkers; dose-dependent MyBP-C protein expression.","TN-401 (PKP2 ARVC) completed dosing in Cohort 2 (6E13 vg/kg); DSMB positive for expansion; Cohort 1 data expected Q4 2025.","DSMB recommended dose expansion for TN-201 after positive safety review; no new meaningful safety events since review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126682,"accession_number":"0001193125-25-272423","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.","Clinical hold based on data previously reviewed by DSMB in summer 2025; DSMB found acceptable safety profile for expansion cohorts.","TN-201 generally well tolerated; no new meaningful safety events since DSMB review.","Tenaya working collaboratively with FDA to resolve hold; expects no impact on data milestones or development timelines.","Company intends to resume dosing once protocol changes are implemented at trial sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143466,"accession_number":"0000950170-25-104164","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.","Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.","TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.","TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.","R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161658,"accession_number":"0000950170-25-079773","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenaya Therapeutics shareholders elect all three Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Goeddel, Ph.D. elected with 80,444,762 votes for, 8,262,596 withheld.","Jeffrey T. Walsh elected with 70,717,277 for, 17,990,081 withheld.","R. Sanders Williams elected with 70,410,874 for, 18,296,484 withheld.","Ratification of Deloitte & Touche LLP passed with 120,339,858 for, 416,705 against, 192,213 abstain.","Broker non-votes of 32,241,417 on each director nominee; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161657,"accession_number":"0000950170-25-065703","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.","Cash, equivalents and investments $88.2M at March 31; March public offering netted $48.8M, extending runway into H2 2026.","TN-201 low-dose cohort showed improved NYHA class in all 3 patients and hypertrophy improvement in 2 of 3; Cohort 2 enrollment on track.","TN-401 RIDGE-1 Phase 1b enrollment on track for H1 2025; initial data expected H2 2025.","Restructuring with workforce reduction estimated at $1.6-$2.7M charges to extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161656,"accession_number":"0000950170-25-055927","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tenaya receives Nasdaq bid price deficiency notice; must regain compliance by Oct 13, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of TNYA common stock below $1.00 for 30 consecutive business days through April 12, 2025.","Nasdaq granted 180-day compliance period ending October 13, 2025; no immediate impact on listing.","To regain compliance, shares must close at $1.00 or higher for at least 10 consecutive business days.","If not cured, Company may seek a second 180-day period by transferring to Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179768,"accession_number":"0001193125-25-067071","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.","Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.","Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.","Cash runway extended into second half of 2026 via cost-containment measures.","Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179767,"accession_number":"0000950170-25-036296","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q4 2024 net loss of $23.8M; cash runway extended to mid-2026 after $48.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).","Cash and investments $61.4M at Dec 31, 2024; after $48.9M March 2025 offering, runway into mid-2026.","Dosing initiated in Cohort 2 (6E13 vg/kg) of MyPEAK-1 Phase 1b/2 trial for TN-201; Cohort 1 data accepted as ACC late-breaker.","First patient dosed in RIDGE-1 Phase 1b trial for TN-401; initial data expected in 2H25; CIRM awarded $8M grant.","Hiro Higa promoted to SVP, Finance and interim principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179766,"accession_number":"0001193125-25-045628","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices $52.5M public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.","Each unit: one share common + Series A warrant (1 share at $0.80, 5yr) + Series B warrant (0.5 share at $0.70, expires June 30, 2026).","Offering expected to close March 5, 2025; Leerink Partners and Piper Sandler are joint book-runners.","Net proceeds to fund development of TN-201 and TN-401, and for working capital.","Company also terminated ATM prospectus under existing sales agreement with Leerink Partners as of March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179765,"accession_number":"0000950170-25-016378","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya appoints interim PAO and reprices CEO underwater options to $1.21","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tomohiro Higa appointed Interim Principal Accounting Officer effective Feb 6, 2025; he remains SVP Finance.","Board repriced CEO Faraz Ali's underwater options: new exercise price $1.21 per share on 915,875 shares.","Prior exercise prices ranged from $5.64 to $15.19; repricing contingent on retention through July 24, 2025.","If CEO exercises before retention date, he must pay the original higher exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179764,"accession_number":"0000950170-25-009946","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics reprices underwater employee stock options to $1.21 per share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Repriced ~4.1M shares of underwater options with original exercise prices $3.06-$21.01 to $1.21 per share.","CMO Whit Tingley's options for 630,982 shares repriced from $3.06-$15.19 to $1.21.","Early exercise requires paying original higher exercise price until Retention Goal (July 24, 2025 or Change in Control).","No change to expiration dates, vesting criteria, or share count; total eligible options cover 4,133,517 shares.","Repricing designed to retain employees without dilutive new grants or cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196534,"accession_number":"0001193125-24-280112","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.","Robust cardiac transduction at Week 8 above preclinical efficacy levels; TN-201 mRNA increased 50% at Week 52 in Patient 1.","MyBP-C protein level increased 3% from Week 8 to 52 in Patient 1; baseline biopsies added for future quantification.","Clinical measures mostly stable/improved: NT-proBNP stable, troponin I normalized in Patient 2; NYHA class improved.","Further data from Cohort 1 and higher-dose Cohort 2 expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196533,"accession_number":"0001193125-24-280092","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics' SVP & Interim PAO Chihiro Saito resigns effective Dec 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chihiro Saito resigned as SVP, Accounting and Financial Operations and Interim Principal Accounting Officer.","Resignation is to pursue another opportunity; not due to any disagreement with Tenaya.","No replacement or timeline for successor announced in the filing.","Departure leaves interim accounting leadership role vacant at the biotech firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196532,"accession_number":"0000950170-24-122342","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.","Cash and investments $79.5M; runway expected into H2 2025.","DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.","Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.","Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212836,"accession_number":"0000950170-24-106817","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics adopts 2024 Inducement Plan, reclassifies director to balance board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Karah Parschauer reclassified from Class I to Class II director to balance board classes (3 per class).","Board reduced size to 9 directors; Parschauer's compensation unchanged, remains on Audit Committee.","Adopted 2024 Inducement Equity Incentive Plan, reserving 1,200,000 shares for new-hire inducement awards.","Plan intended as material inducement for new employees; no shareholder approval required under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212835,"accession_number":"0000950170-24-093991","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.","Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.","TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.","TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.","CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212834,"accession_number":"0001193125-24-184817","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics CFO Leone Patterson resigning effective Aug 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leone Patterson, Chief Financial and Business Officer, resigns to pursue another opportunity; will remain until August 14, 2024.","Resignation is not due to any disagreement with Tenaya on financials, operations, policies, or practices.","Company has initiated a search for a new Chief Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231893,"accession_number":"0000950170-24-078585","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics Director Jin-Long Chen Resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jin-Long Chen resigned as a director of Tenaya Therapeutics on June 25, 2024.","Chen also stepped down from the Corporate Governance & Nominating Committee.","Resignation was voluntary and not due to any disagreement with the company or board.","Ticker TNYA on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231892,"accession_number":"0000950170-24-067318","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenaya stockholders elect three Class III directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Faraz Ali elected with 60,262,398 votes for, 157,949 withheld; broker non-votes 10,386,279.","June Lee elected with 60,205,014 for, 215,333 withheld; broker non-votes same.","Deepak Srivastava elected with 53,643,731 for, 6,776,616 withheld; broker non-votes same.","Ratification of Deloitte & Touche as independent auditor passed: 70,778,448 for, 16,045 against, 12,133 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231891,"accession_number":"0000950170-24-059539","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01","2.05"],"status":"ready","headline":"Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.","Cash $122.2M at Mar 31; Feb follow-on raised $46.8M net; runway into H2 2025.","Workforce reduced ~22% with $1.3-1.5M severance charges expected in Q2 2024.","TN-201 initial Phase 1b data expected H2 2024; TN-401 RIDGE-1 sites activated.","Hired Dr. Whedy Wang as SVP Biometrics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}